Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR4330] to CD41
- Suitable for: ICC/IF, WB, IHC-P
- Reacts with: Mouse, Human
Product nameAnti-CD41 antibody [EPR4330]
See all CD41 primary antibodies
DescriptionRabbit monoclonal [EPR4330] to CD41
Mouse reactivity is only guaranteed for IHC-P.
Tested applicationsSuitable for: ICC/IF, WB, IHC-Pmore details
Unsuitable for: IP
Species reactivityReacts with: Mouse, Human
Synthetic peptide within Human CD41 aa 50-150 (extracellular). The exact sequence is proprietary. Synthetic peptide corresponding to residues in the extracellular domain in Human CD41.
Database link: P08514
- Human platelet, fetal liver and placenta lysates; Human spleen tissue
Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% Tris glycine, 0.88% Sodium chloride, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab134131 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use at an assay dependent concentration.|
|WB||1/1000 - 1/10000. Predicted molecular weight: 113 kDa.|
|IHC-P||1/100 - 1/250. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.|
FunctionIntegrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It recognizes the sequence R-G-D in a wide array of ligands. It recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial cell surface.
Tissue specificityIsoform 1 and isoform 2 were identified in platelets and megakaryocytes, but not in reticulocytes or in Jurkat and U937 white blood cell line. Isoform 3 is expressed by leukemia, prostate adenocarcinoma and melanoma cells but not by platelets or normal prostate or breast epithelial cells.
Involvement in diseaseDefects in ITGA2B are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. GT is the most common inherited disease of platelets. It is an autosomal recessive disorder characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb/beta-3 complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the glycoprotein IIb/beta-3 complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT 'variants' have normal or near normal (60-100%) expression of dysfunctional receptors.
Sequence similaritiesBelongs to the integrin alpha chain family.
Contains 7 FG-GAP repeats.
- Information by UniProt
- antigen CD41 antibody
- BDPLT16 antibody
- BDPLT2 antibody
Ab134131 staining CD41 in paraffin embedded Human bone marrow tissue sections by Immunohistochemistry. Heat mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0). Samples were incubated with primary antibody at 1/2000 dilution (0.30 μg/ml). A ready to use Goat Anti-rabbit IgG H&L (HRP) was used as the secondary antibody. Hematoxylin was used as a counterstain. Cytoplasmic staining in megakaryocytes of human bone marrow (PMID: 27128503; PMID: 23667055).
All lanes : Anti-CD41 antibody [EPR4330] (ab134131) at 0.6 µg/ml
Lane 1 : HEL (human Erythroleukemia erythroblast) whole cell lysate
Lane 2 : K-562 (human chronic myelogenous leukemia lymphoblast) whole cell lysate
Lysates/proteins at 20 µg per lane.
All lanes : VeriBlot for IP Detection Reagent (HRP) (ab131366) at 1/1000 dilution
Predicted band size: 113 kDa
Exposure time: 3 minutes
Blocking and diluting buffer: 5% NFDM/TBST.
Negative control: K-562 (PMID 2458779)
Ab134131 staining CD41 in HEL (human Erythroleukemia erythroblast) cells by ICC/IF (Immunocytochemistry/Immunofluorescence. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% TritonX-100. Samples were incubated with primary antibody at 1/100 dilution (6 μg/ml). An AlexaFluor® 488 Goat anti-Rabbit (ab150077) was used as the secondary antibody at 1/1000 dilution (2 μg/ml). Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) , ab195889 was used a counterstain antibody at 1/200 dilution (2.5 μg/ml). DAPI was used as a nuclear counterstain. Confocal image showing membranous staining in HEL cell line.
Negative control: K562( PMID 2458779)
Ab134131 staining CD41 paraffin embedded Mouse bone marrow tissue sections by Immunohistochemistry. Heat mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0). Samples were incubated with primary antibody at 1/500 dilution (1.21 μg/ml). A ready to use Goat Anti-rabbit IgG H&L (HRP) was used as the secondary antibody. Hematoxylin was used as a counterstain. Cytoplasmic staining in megakaryocytes of mouse bone marrow (PMID: 27128503).
All lanes : Anti-CD41 antibody [EPR4330] (ab134131) at 1/1000 dilution
Lane 1 : Human platelet lysate
Lane 2 : Human fetal liver lysate
Lane 3 : Human placenta lysate
Lysates/proteins at 10 µg per lane.
All lanes : HRP labelled goat anti rabbit at 1/2000 dilution
Predicted band size: 113 kDa
ab134131 has been referenced in 10 publications.
- Zhu W et al. CD41-deficient exosomes from non-traumatic femoral head necrosis tissues impair osteogenic differentiation and migration of mesenchymal stem cells. Cell Death Dis 11:293 (2020). PubMed: 32341357
- Wei H et al. 2-Aminoethoxydiphenylborate (2-APB) inhibits release of phosphatidylserine-exposing extracellular vesicles from platelets. Cell Death Discov 6:10 (2020). PubMed: 32140260
- Coppin L et al. Clinical Protocol to Prevent Thrombogenic Effect of Liver-Derived Mesenchymal Cells for Cell-Based Therapies. Cells 8:N/A (2019). PubMed: 31394759
- Wei H & Harper MT ABT-737 Triggers Caspase-Dependent Inhibition of Platelet Procoagulant Extracellular Vesicle Release during Apoptosis and Secondary Necrosis In Vitro. Thromb Haemost 19:1665-1674 (2019). PubMed: 31493778
- Shang C et al. The human platelet transcriptome and proteome is altered and pro-thrombotic functional responses are increased during prolonged hypoxia exposure at high altitude. Platelets N/A:1-10 (2019). PubMed: 30721642
- Chen Y et al. Platelet-membrane-camouflaged bismuth sulfide nanorods for synergistic radio-photothermal therapy against cancer. Biomater Sci 7:3450-3459 (2019). PubMed: 31268067
- Wei H et al. Lipid rafts are essential for release of phosphatidylserine-exposing extracellular vesicles from platelets. Sci Rep 8:9987 (2018). PubMed: 29968812
- Jamaly S et al. Elevated plasma levels of P-selectin glycoprotein ligand-1-positive microvesicles in patients with unprovoked venous thromboembolism. J Thromb Haemost N/A:N/A (2018). PubMed: 29851269
- Li H et al. Identification of curcumin-inhibited extracellular matrix receptors in non-small cell lung cancer A549 cells by RNA sequencing. Tumour Biol 39:1010428317705334 (2017). PubMed: 28618934
- Kuo HH et al. Platelets in Early Antibody-Mediated Rejection of Renal Transplants. J Am Soc Nephrol N/A:N/A (2014). IHC-P ; Human . PubMed: 25145937